GlassScriptPhysician profile
Rajiv Goyal
NPI 1710474671
$2,290.07
in general payments reported to CMS, 2019-2025
22 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $24.31 · 2021: $202 · 2022: $490 · 2023: $334 · 2024: $605 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $657.24 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $465.74 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $437.79 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Edwards Lifesciences Corporation | $206.88 | 2020-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $86.56 | 2024 | Lifevest |
| Amgen INC. | $78.62 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $47.38 | 2025 | |
| Pfizer INC. | $47.04 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $25.21 | 2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $24.03 | 2025 | |
| Abbott Laboratories | $23.54 | 2025 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.29 | 2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $22.72 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $21.34 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.51 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $16.05 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.65 | 2022 | |
| Sobi, INC | $14.92 | 2021 | |
| Phadia US INC. | $14.61 | 2025 | Immunocap |
| Exact Sciences Corporation | $13.75 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $13.66 | 2024 | Gemtesa |
| Eisai INC. | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.